CURE PDS
The Product Disclosure Statement (PDS) explains the fees, tax status and some of the risks.
Menu
The Global X CURE ETF provides investors with exposure to the US biotechnology sub-industry within the health care sector. CURE adopts an equally weighted strategy, which allocates greater exposure to small and mid-cap shares compared to a market capitalisation weighted approach.
The CURE ETF invests in biotechnology stocks trading on major US exchanges. CURE tracks the performance of the S&P Biotechnology Select Industry Index by holding all of the shares that make up the index, closely in proportion to their index weights. These companies are classified as belonging to the GICS biotechnology sub-industry, and must meet certain market capitalisation and liquidity requirements.
CURE could be used by investors to get tactical exposure to a basket of companies within the USA’s biotechnology industry. Most biotech companies are heavily research-focused and their success can often depend on one breakthrough or regulatory approval, making it a speculative industry.
To invest in any ASX ETF, you need to use create your own broker account and choose from over 400 ETFs.
But why bother do that when you can get everything done for you – for a simple, low, fee?
We manage ETF portfolios on behalf of 250+ Australian investors, with over $20 million invested.
Simple. Low cost. Transparent. Professional.
It’s called Rask Invest.
Click the button to discover the ETFs we own, and how it works.
*The warnings on this page are applied by our ETF research team. Please know that these warnings are based on quantitative metrics and our internal methodology. These risks are not exhaustive and therefore they should not be relied upon. Always read the PDS of the function and speak to your financial adviser before acting on this information.
The information on this website is general financial advice only. That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire any financial product. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please read our Terms & Conditions and Financial Services Guide before using this website.
“Rask Invest” is considered a financial product and has a Product Disclosure Statement (PDS) and Target Market Determination (TMD), issued by InvestSMART. These documents can be accessed on the Rask Invest website. Please seek professional advice before making any investment decision with respect to Rask Invest.
© Rask Australia 2024
